Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.961
EU - Europa 3.898
AS - Asia 1.133
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 3
OC - Oceania 3
Totale 16.024
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.700
SE - Svezia 750
IE - Irlanda 735
IT - Italia 674
CN - Cina 615
DE - Germania 499
UA - Ucraina 424
HK - Hong Kong 252
GB - Regno Unito 226
CA - Canada 222
FI - Finlandia 143
AT - Austria 117
VN - Vietnam 99
DK - Danimarca 82
TR - Turchia 71
FR - Francia 60
RO - Romania 45
IN - India 43
RU - Federazione Russa 43
BE - Belgio 38
MX - Messico 29
SG - Singapore 17
NL - Olanda 16
PL - Polonia 16
IR - Iran 14
BR - Brasile 9
EU - Europa 9
JP - Giappone 6
CH - Svizzera 5
HN - Honduras 5
BZ - Belize 4
ES - Italia 4
PT - Portogallo 4
BG - Bulgaria 3
CL - Cile 3
ID - Indonesia 3
KR - Corea 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AR - Argentina 2
AU - Australia 2
CZ - Repubblica Ceca 2
EE - Estonia 2
EG - Egitto 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BS - Bahamas 1
BY - Bielorussia 1
GR - Grecia 1
IL - Israele 1
JO - Giordania 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
Totale 16.024
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Houston 1.015
Chandler 745
Dublin 718
Ashburn 630
Jacksonville 565
Wilmington 538
Seattle 464
Cambridge 436
Frankfurt am Main 395
Dearborn 319
New York 308
Princeton 279
Hong Kong 250
Milan 217
Nanjing 147
Altamura 133
Lawrence 133
Vienna 112
Lachine 110
Shanghai 88
Dong Ket 83
San Diego 72
Beijing 64
Ottawa 55
Andover 51
Fremont 50
Nanchang 46
Galati 43
Boardman 42
Hebei 41
Brussels 38
Shenyang 38
Los Angeles 34
London 32
Helsinki 31
Toronto 29
Norwalk 28
Falls Church 25
Hangzhou 20
Tianjin 19
Cuauhtémoc 18
Changsha 17
Edmonton 16
Pune 16
Buffalo 15
Guangzhou 15
Kunming 15
Jiaxing 14
Mountain View 14
Rome 12
Jinan 11
Kiev 10
Loreto 10
Washington 10
Detroit 9
San Mateo 9
Chicago 8
Monza 8
Ningbo 8
Zhengzhou 8
Brescia 7
Clearwater 7
Lissone 7
Redmond 7
Auburn Hills 6
Bologna 6
Kilburn 6
San Giuliano Milanese 6
Sesto San Giovanni 6
Bari 5
Dallas 5
Hanoi 5
Laurel 5
Phoenix 5
San Francisco 5
São Paulo 5
Taizhou 5
Tegucigalpa 5
Turin 5
Belize City 4
Carate Brianza 4
Enterprise 4
Hounslow 4
Huizen 4
Lanzhou 4
Leawood 4
Nürnberg 4
Piacenza 4
Polska 4
Stockholm 4
Winnipeg 4
Bergamo 3
Casper 3
Columbus 3
Como 3
Edinburgh 3
Fuzhou 3
Totale 12.847
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 265
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 224
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 211
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 210
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 208
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 202
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 201
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 194
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 193
HIV testing: A must for patients with inflammatory bowel disease 181
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 179
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 179
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 178
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 173
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 173
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 173
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 170
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 168
Focal bone lesions in hiv-positive patient treated with tenofovir 167
Brachial and central blood pressure in HIV-infected subjects 167
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 166
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 164
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 162
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 161
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 161
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 158
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 158
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 158
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 156
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 155
Unmasking tuberculosis in the era of antiretroviral treatment 152
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 152
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 152
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 151
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 151
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 149
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 149
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 148
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 147
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 146
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 146
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 145
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 137
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 136
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 135
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 135
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 135
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 134
Strategies to limit immune-activation in HIV patients 134
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 133
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 132
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 132
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 132
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 132
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 131
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 130
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 130
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 128
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 127
Beyond the gut bacterial microbiota: The gut virome 127
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 126
Antimicrobial therapy duration: A major matter in the management of severe infections 125
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 124
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 123
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 123
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 123
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 123
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 121
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 118
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 117
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 117
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 116
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 115
The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study) 111
To the editor 111
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 111
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 111
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 109
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 107
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme 106
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 105
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 105
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 105
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 104
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: Results from the Italian MASTER Cohort 104
Immunity to human immunodeficiency virus (HIV) infection 103
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 102
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 101
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 101
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 101
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 100
Exogenous reinfection of tuberculosis in a low-burden area 99
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 99
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 98
Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and Beijing/W family of Mycobacterium tuberculosis 98
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 98
Letter: Antibiotic dose adjustment in patients with advanced liver disease 97
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study 97
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 96
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 95
Totale 13.928
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.731
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.731
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.069 0 0 0 0 0 0 0 0 0 235 424 410
2019/20203.560 448 215 255 280 281 410 389 281 391 235 271 104
2020/20212.067 151 222 233 223 145 119 184 151 162 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.943 369 803 233 291 188 472 41 175 218 31 75 47
2023/20241.878 46 75 100 85 288 561 435 82 153 53 0 0
Totale 16.932